Cancer Letters
Volume 319, Issue 2 , Pages 232-241 , 28 June 2012

Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition

  • Siker Kimbung

      Affiliations

    • Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden
    • CREATE Health Strategic Center for Translational Cancer Research, Lund University, Lund, Sweden
    • ,
  • Ewa Biskup

      Affiliations

    • Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden
    • CREATE Health Strategic Center for Translational Cancer Research, Lund University, Lund, Sweden
    • Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland
    • ,
  • Ida Johansson

      Affiliations

    • Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden
    • CREATE Health Strategic Center for Translational Cancer Research, Lund University, Lund, Sweden
    • ,
  • Kristina Aaltonen

      Affiliations

    • Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden
    • CREATE Health Strategic Center for Translational Cancer Research, Lund University, Lund, Sweden
    • ,
  • Astrid Ottosson-Wadlund

      Affiliations

    • Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
    • ,
  • Sofia Gruvberger-Saal

      Affiliations

    • Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden
    • CREATE Health Strategic Center for Translational Cancer Research, Lund University, Lund, Sweden
    • ,
  • Heather Cunliffe

      Affiliations

    • Translational Genomics Research Institute, Phoenix, AZ, United States
    • ,
  • Bengt Fadeel

      Affiliations

    • Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
    • ,
  • Niklas Loman

      Affiliations

    • Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden
    • CREATE Health Strategic Center for Translational Cancer Research, Lund University, Lund, Sweden
    • ,
  • Pontus Berglund

      Affiliations

    • Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden
    • CREATE Health Strategic Center for Translational Cancer Research, Lund University, Lund, Sweden
    • ,
  • Ingrid Hedenfalk

      Affiliations

    • Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden
    • CREATE Health Strategic Center for Translational Cancer Research, Lund University, Lund, Sweden
    • Corresponding Author InformationCorresponding author at: Department of Oncology, Clinical Sciences, Lund University, BMC C13, SE-22184 Lund, Sweden. Tel.: +46 46 2220652; fax: +46 46 147327.

Received 14 July 2011 ,Revised 30 December 2011 ,Accepted 11 January 2012.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0304-3835(12)00045-6

doi: 10.1016/j.canlet.2012.01.015

Cancer Letters
Volume 319, Issue 2 , Pages 232-241 , 28 June 2012

Article Tools

* Image Usage & Resolution